Comparative serological screening of immnoproteomes of healthy individuals and patients with multiple myeloma in the long-lasting remission

Zuzana Bilkova, Department of Biological and Biochemical Sciences, University of Pardubice , Pardubice, Czech Republic (Zuzana.Bilkova@upce.cz)
Eliska Zelinkova, Department of Biological and Biochemical Sciences, University of Pardubice, Pardubice, Czech Republic
Jana Machkova, Department of Biological and Biochemical Sciences, University of Pardubice, Pardubice, Czech Republic
Vladimir Maisnar, 4th Department of Medicine - Hematology, Faculty Hospital and Charles University, Hradec Kralove, Czech Republic
Luděk Pour, Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
Sabina Sevcikova, Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic

Spontaneous tumor regression is a phenomenon that has been observed throughout the history of mankind. After having been the subject of many disagreements, it is now accepted as an indisputable fact. This remarkable phenomenon has been observed in multiple myeloma patients who developed an aplastic anemia-like (AA-like) syndrome after the high-dose therapy (HDT) with autologous stem cell transplantation (ASCT). In order to provide novel insights into this phenomenon and to accelerate development of new treatment against these diseases, detail characterization of immunoproteome is an essential prelude.

In this work the sera of patients suffered from multiple myeloma currently in the long-lasting remission have been applied for detailed serological proteome analysis (SERPA) to screen its reactivity against antigens isolated from two representative cancer cell lines (HEL 92.1.7. and SKBR3). SERPA, as a tool for identification of new candidate immunoreactive antigens is a promising method in this respect. Comparative probing of the sera of patients and healthy individuals against specific antigens can be valuable for recognition of numerous reliable biomarkers associated with particular disease or specific stage of disease development. The identified candidate molecules will be essential not only for diagnostic but also prognostic or even therapeutic applications.

---

Abstract Reference & Short Personal Biography of Presenting Author

Zuzana Bilkova graduated in Molecular Biology and Genetics at Charles University (Prague, CZ) and currently she is a professor of Immunology and Immunochemistry at the University of Pardubice (CZ). During her twenty-year academic career, she has been named as a head of Department of Biological and Biochemical Sciences. Her scientific expertise can be summarized: surface modification and biofunctionalization of nanomaterials and their application in immunochemistry, bioaffinity chromatography and biosensing. Up to the present days, she has published more than 110 papers and gave more than 45 oral presentations at seminars, workshops, conferences.